Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 11CNS 10Gastrointestinal 8Breast 5Head & Neck 4Sarcoma 3Genitourinary 3Other solid neoplasm 2Endocrine 2Tumor-Agnostic 1Other neoplasm 1NET 1

Conditions

Gliosarcoma 3Glioblastoma 3Glioma 2Brain Neoplasms 2

Interventions

Radiotherapy 137Cyclophosphamide 132Temozolomide 116Doxorubicin 99Filgrastim 68Ifosfamide 64Gemcitabine 58Etoposide 55Bevacizumab 51Imatinib Mesylate 50fludarabine phosphate 49Irinotecan 46pembrolizumab 45Peripheral Blood Stem Cell Transplantation 45pazopanib 43Magnetic Resonance Spectroscopy 42Methotrexate 40Carboplatin 40Busulfan 40Vincristine 38Surgical Procedures, Operative 37Nivolumab 37Melphalan 37Cisplatin 36Radiation 34Blood Specimen Collection 33Mycophenolic Acid 31Cyclosporine 31Docetaxel 29Trabectedin 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × vandetanib × Sarcoma × Clear all
NCT00441142 2019-03-05

Zactima

Dana-Farber Cancer Institute

Phase 1/2 Completed
119 enrolled 15 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT00613223 2013-02-20

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

Duke University

Phase 1 Completed
49 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT00613054 2012-12-05

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

Duke University

Phase 1 Completed
27 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡